Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ketamine/Peripartum

Ketamine for Peripartum

3 papers and 8 clinical trials exploring ketamine as a treatment for peripartum.

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
IndicationApproximately 15-20% of women experience postpartum depression worldwide.

Peripartum

Peripartum depression, including postpartum depression (PPD), is a significant mental health issue affecting new mothers, characterised by severe mood changes following childbirth. Current research into psychedelic treatments, particularly with compounds like esketamine and psilocybin, shows promising potential to alleviate depressive symptoms in this demographic.

Full Peripartum profile

Academic Research

3 papers
Paywallmeta

A single intravenous administration of a sub-anesthetic ketamine dose during the perioperative period of cesarean section for preventing postpartum depression: A meta-analysis

This meta-analysis (2022) explores the use of ketamine in offsetting postpartum depression (PPD). It was found that the score and the prevalence of PPD within 1 week postpartum were significantly reduced, whereas the PPD score after 4 weeks postpartum showed no superiority. 0.5mg/kg of ketamine was found to be efficacious.

Published
April 1, 2022
Journal
Psychiatry Research
Authors
Li, Q., Wang, S., Mei, X.
Open Accessindividual

The effect of ketamine on preventing postpartum depression

In a double‑blind randomised trial of 134 women undergoing scheduled caesarean section, a single 0.5 mg/kg dose of ketamine given during anaesthetic induction significantly lowered Edinburgh Postnatal Depression Scale scores at two and four weeks versus control. These findings indicate ketamine may help prevent postpartum depression, but larger studies are required to confirm efficacy and safety.

Published
January 1, 2021
Journal
Journal of Medicine and Life
Authors
Alipoor, M., Loripoor, M., Kazemi, M., Farahbakhsh, F., Sarkoohi, A.
Paywallindividual

Single bolus low-dose of ketamine does not prevent postpartum depression: a randomized, double-blind, placebo-controlled, prospective clinical trial

This randomised-controlled trial (n=330) assessed the efficacy of low-dose ketamine (17.5mg/70kg diluted to 10 mL with 0.9% saline) administered during caesarean section in preventing postpartum depression (PPD). No significant differences were found in the prevalence of PPD between the active group and the placebo group at 3 days and 6 weeks after delivery. Pain scores were significantly different at 6 weeks only.

Published
March 29, 2017
Journal
Archives of Gynecology and Obstetrics
Authors
Yang, X., Yuantao, L., Xialei, H., Daili, C., Baozuan, S., Daqing, M.

Clinical Trials

8 trials
RecruitingPhase I

Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery (PREPARE-2)

Phase I interventional study (n=50) comparing ketamine pharmacokinetics and pharmacodynamics in postpartum cesarean patients versus healthy controls using a 12-hour infusion (0.18 mg/kg/hr x1 h loading then 0.05 mg/kg/hr x11 h maintenance).

Started
February 7, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06767566
Unknown statusPhase NA

Dose Low Dose Ketamine in Casesarian

Prospective case-control observational study (n=150) comparing single-dose IV ketamine (0.5 mg/kg), ketamine plus midazolam, and saline placebo in patients undergoing caesarean section to evaluate postpartum depression and postoperative outcomes.

Started
June 1, 2024
Type
observational
Randomized
No
Registry ID
NCT06237569
WithdrawnPhase II/III

The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series (SMILES)

Open-label case series (n=25) assessing feasibility of Perinatal SMILES (interpersonal psychotherapy plus two subcutaneous ketamine doses ~24 h apart) to improve post-cesarean mood in low-income women.

Started
May 1, 2024
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06048263
CompletedPhase III

Ketamine to Prevent PPD After Cesarean

Randomised, parallel pilot study (n=25 actual) testing ketamine 0.5 mg/kg by subcutaneous injection or 40-minute IV infusion versus saline placebo to prevent postpartum depression after cesarean, with 42-day follow-up.

Started
December 11, 2020
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04227704
CompletedPhase NA

Low-dose S-ketamine in Women With Prenatal Depression

Randomised, parallel-group prevention trial (n=364) testing a single low-dose S-ketamine infusion (0.2 mg/kg IV) after childbirth to reduce postpartum depression in women with prenatal depression.

Started
June 19, 2020
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04414943
TerminatedPhase II

Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression

Randomised, crossover Phase II study (n=1) testing single IV ketamine infusions 0.5 mg/kg and 0.2 mg/kg in postpartum depression to assess safety, pharmacokinetics and antidepressant efficacy.

Started
April 3, 2019
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04011592

Explore further

Search all Ketamine papers Search all Peripartum trials Full Ketamine profile Full Peripartum profile